EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population

Antzeko izenburuak

• Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
  nork: Kim, Lucia, et al.
  Argitaratua: (2017)
• Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
  nork: Copeman, Michael
  Argitaratua: (2008)
• A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting
  nork: Gridelli, Cesare, et al.
  Argitaratua: (2016)
• A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
  nork: Hirsch, Fred R., et al.
  Argitaratua: (2011)
• Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
  nork: Reguart, Noemí, et al.
  Argitaratua: (2010)